Literature DB >> 18974777

Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy.

H J Mauceri1, M A Beckett, H Liang, H G Sutton, S Pitroda, E Galka, E Efimova, T Darga, N N Khodarev, C R King, M C Posner, S Hellman, D W Kufe, R R Weichselbaum.   

Abstract

TNFerade is a radioinducible adenoviral vector expressing tumor necrosis factor-alpha (TNF-alpha) (Ad.Egr-TNF) currently in a phase III trial for inoperable pancreatic cancer. We studied B16-F1 melanoma tumors in TNF receptor wild-type (C57BL/6) and deficient (TNFR1,2-/- and TNFR1-/-) mice. Ad.Egr-TNF+IR inhibited tumor growth compared with IR in C57BL/6 but not in receptor-deficient mice. Tumors resistant to TNF-alpha were also sensitive to Ad.Egr-TNF+IR in C57BL/6 mice. Ad.Egr-TNF+IR produced an increase in tumor-associated endothelial cell apoptosis not observed in receptor-deficient animals. Also, B16-F1 tumors in mice with germline deletions of TNFR1,2, TNFR1 or TNF-alpha, or in mice receiving anti-TNF-alpha exhibited radiosensitivity. These results show that tumor-associated endothelium is the principal target for Ad.Egr-TNF radiosensitization and implicate TNF-alpha signaling in tumor radiosensitivity.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18974777      PMCID： PMC5705082          DOI： 10.1038/cgt.2008.86

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN： 0929-1903            Impact factor:   5.987


  45 in total

1.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

2.  Diverse TNFalpha-induced death pathways are enhanced by inhibition of NF-kappaB.

Authors:  Mukta Katdare; Elena V Efimova; Edwardine Labay; Nikolai N Khodarev; Thomas E Darga; Michael Garofalo; Satoaki Nakamura; Donald W Kufe; Mitchell C Posner; Ralph R Weichselbaum
Journal:  Int J Oncol       Date:  2007-12       Impact factor: 5.650

Review 3.  TNF receptor subtype signalling: differences and cellular consequences.

Authors:  David J MacEwan
Journal:  Cell Signal       Date:  2002-06       Impact factor: 4.315

4.  TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice.

Authors:  Thomas Calzascia; Marc Pellegrini; Håkan Hall; Laurent Sabbagh; Nobuyuki Ono; Alisha R Elford; Tak W Mak; Pamela S Ohashi
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

5.  Inhibition of the tumor necrosis factor-alpha pathway is radioprotective for the lung.

Authors:  Ming Zhang; Jun Qian; Xianying Xing; Feng-Ming Kong; Lujun Zhao; Ming Chen; Theodore S Lawrence
Journal:  Clin Cancer Res       Date:  2008-03-15       Impact factor: 12.531

6.  IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis.

Authors:  James E Vince; W Wei-Lynn Wong; Nufail Khan; Rebecca Feltham; Diep Chau; Afsar U Ahmed; Christopher A Benetatos; Srinivas K Chunduru; Stephen M Condon; Mark McKinlay; Robert Brink; Martin Leverkus; Vinay Tergaonkar; Pascal Schneider; Bernard A Callus; Frank Koentgen; David L Vaux; John Silke
Journal:  Cell       Date:  2007-11-16       Impact factor: 41.582

7.  Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study.

Authors:  D R Spriggs; M L Sherman; H Michie; K A Arthur; K Imamura; D Wilmore; E Frei; D W Kufe
Journal:  J Natl Cancer Inst       Date:  1988-09-07       Impact factor: 13.506

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Tumor response to radiotherapy regulated by endothelial cell apoptosis.

Authors:  Monica Garcia-Barros; Francois Paris; Carlos Cordon-Cardo; David Lyden; Shahin Rafii; Adriana Haimovitz-Friedman; Zvi Fuks; Richard Kolesnick
Journal:  Science       Date:  2003-05-16       Impact factor: 47.728

10.  Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis.

Authors:  Jan-Hendrik Egberts; Vera Cloosters; Andreas Noack; Bodo Schniewind; Lutz Thon; Stefanie Klose; Bastian Kettler; Corinna von Forstner; Christian Kneitz; Jürgen Tepel; Dieter Adam; Harald Wajant; Holger Kalthoff; Anna Trauzold
Journal:  Cancer Res       Date:  2008-03-01       Impact factor: 12.701
View more
  9 in total

Review 1.  The role of radiotherapy in locally advanced pancreatic carcinoma.

Authors:  Ruchika Gutt; Stanley L Liauw; Ralph R Weichselbaum
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-07-13       Impact factor: 46.802

Review 2.  Current position of TNF-α in melanomagenesis.

Authors:  Iuliana Nenu; Diana Tudor; Adriana Gabriela Filip; Ioana Baldea
Journal:  Tumour Biol       Date:  2015-08-18

3.  Ad.Egr-TNF and local ionizing radiation suppress metastases by interferon-beta-dependent activation of antigen-specific CD8+ T cells.

Authors:  Yuru Meng; Helena J Mauceri; Nikolai N Khodarev; Thomas E Darga; Sean P Pitroda; Michael A Beckett; Donald W Kufe; Ralph R Weichselbaum
Journal:  Mol Ther       Date:  2010-03-02       Impact factor: 11.454

4.  Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.

Authors:  Joseph M Herman; Aaron T Wild; Hao Wang; Phuoc T Tran; Kenneth J Chang; Gretchen E Taylor; Ross C Donehower; Timothy M Pawlik; Mark A Ziegler; Hongyan Cai; Dionne T Savage; Marcia I Canto; Jason Klapman; Tony Reid; Raj J Shah; Sarah E Hoffe; Alexander Rosemurgy; Christopher L Wolfgang; Daniel A Laheru
Journal:  J Clin Oncol       Date:  2013-01-22       Impact factor: 44.544

Review 5.  Tumour necrosis factor and cancer.

Authors:  Frances Balkwill
Journal:  Nat Rev Cancer       Date:  2009-04-03       Impact factor: 60.716

6.  A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.

Authors:  T Y Seiwert; T Darga; D Haraf; E A Blair; K Stenson; E E W Cohen; J K Salama; V Villaflor; M E Witt; M W Lingen; R R Weichselbaum; E E Vokes
Journal:  Ann Oncol       Date:  2012-10-26       Impact factor: 32.976

7.  Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy.

Authors:  Yuru Meng; Michael A Beckett; Hua Liang; Helena J Mauceri; Nico van Rooijen; Kenneth S Cohen; Ralph R Weichselbaum
Journal:  Cancer Res       Date:  2010-02-09       Impact factor: 12.701

8.  STAT1 pathway mediates amplification of metastatic potential and resistance to therapy.

Authors:  Nikolai N Khodarev; Paul Roach; Sean P Pitroda; Daniel W Golden; Mihir Bhayani; Michael Y Shao; Thomas E Darga; Mara G Beveridge; Ravi F Sood; Harold G Sutton; Michael A Beckett; Helena J Mauceri; Mitchell C Posner; Ralph R Weichselbaum
Journal:  PLoS One       Date:  2009-06-08       Impact factor: 3.240

9.  Efficacy of pEgr-1-endostatin combined with ionizing radiation on hypoxic conditions in nude mice bearing SKOV3 ovarian carcinoma.

Authors:  Yong-Chun Zhang; Xiu-Mei Li; Zhuang Yu; Xiao-Li Shi; Yong Li; Wan-Lin Wang
Journal:  Oncol Lett       Date:  2017-01-02       Impact factor: 2.967
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.